KUSTE BIOPHARMA expands the use of these molecules to inflammatory urological diseases whose medical needs are currently unmet, such as Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS).
Existing clinical data also support other possible developments, for example on Inflammatory Bowel Disease (IBD).
KUSTE BIOPHARMA has closed a relevant financial round to launch Phase 2 clinical studies on IC/PBS and preclinical studies on other applications.